10-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K/A
(Amendment No. 1)

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2004

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________.

Commission File Number 000-23357
BIOANALYTICAL SYSTEMS, INC.
(Exact name of the registrant as specified in its charter)

INDIANA (State or other jurisdiction of
incorporation or organization)


2701 KENT AVENUE
WEST LAFAYETTE, INDIANA (Address of principal executive offices)
35-1345024 (I.R.S. Employer
Identification No.)


47906 (Zip code)

(765) 463-4527 (Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:  None

Securities registered pursuant to section 12(g) of the Act:  Common Shares

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES      NO 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2).    YES     NO

Based on the closing price on the NASDAQ stock market on January 10, 2005, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant is $18,297,510. As of January 10, 2005, 4,869,502 shares of registrant's common shares were outstanding. No shares of registrant's Preferred Stock were outstanding as of January 10, 2004.

EXPLANATORY NOTE

The Company is filing this Amendment No. 1 to Annual Report on Form 10-K/A which was for the fiscal year ended September 30, 2004, solely to correct a typographical error in the Section 1350 Certifications contained in Exhibit 32. Except for the item noted above, no other information is being amended by this Form 10-K/A. The Company has not updated disclosures in this Form 10-K/A to reflect any event subsequent to the Company’s filing of the original Form 10-K.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:  January 25, 2005 BIOANALYTICAL SYSTEMS, INC.
(Registrant)



By:  /s/ Peter T. Kissinger Peter T. Kissinger
President, Chairman and Chief Executive
Officer



By:  /s/ Michael R. Cox Michael R. Cox
Vice President, Finance, Chief Financial
Officer and Treasurer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature Capacity Date

/s/  Peter T. Kissinger Peter T. Kissinger President, Chairman and Chief
Executive Officer and Director
(Principal Executive Officer) January 25, 2005

/s/  Michael R. Cox Michael R. Cox Vice President, Finance, Chief Financial
Officer and Treasurer
(Principal Financial and Accounting Officer) January 25, 2005

/s/  William E. Baitinger William E. Baitinger Director January 25, 2005

/s/  David W. Crabb David W. Crabb Director January 25, 2005

Gayl W. Doster Director January __, 2005

/s/  Candice B. Kissinger Candice B. Kissinger Director January 25, 2005

/s/  Ronald E. Shoup Ronald E. Shoup Director January 25, 2005

Leslie B. Daniels Director January __, 2005

W. Leigh Thompson Director January __, 2005

EX-32

Exhibit 32

I, Peter T. Kissinger, the Chairman of the Board; President; and Chief Executive Officer of Bioanalytical Systems, Inc., certify that (i) the Annual Report on Form 10-K for the year ended September 30, 2004, (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bioanalytical Systems, Inc. as of the dates and for the periods set forth therein.

/s/  Peter T. Kissinger Peter T. Kissinger
Chairman of the Board,
President and
Chief Executive Officer
January 12, 2005

I, Michael R. Cox, the Vice President, Finance; Chief Financial Officer; and Treasurer of Bioanalytical Systems, Inc., certify that (i) the Annual Report on Form 10-K for the year ended September 30, 2004, (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bioanalytical Systems, Inc. as of the dates and for the periods set forth therein.

/s/  Michael R. Cox Michael R. Cox
Vice President, Finance, Chief Financial
Officer and Treasurer
January 12, 2005